David S. Hong, MD, on NSCLC: Durability of Clinical Benefit and Biomarkers in Patients Treated With Sotorasib

September 20, 2020 By The ASCO Post Staff

David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings on sotorasib, a novel, first-in-class, oral KRASG12C inhibitor. The agent demonstrated durable disease control in heavily pretreated patients with non–small cell lung cancer (Abstract 1257O).

Related Content